Windlas Biotech Q2 FY27 Results and Board Leadership Restructuring
Windlas Biotech Ltd · Change in Management · 05 Nov 2026, 10:55 pm
Windlas Biotech Q2 FY27 Results and Board Leadership Restructuring Windlas Biotech reported Q2 FY27 revenue from operations of ₹2,639.08m, up 18.7% YoY from ₹2,223.98m and 6.4% QoQ from ₹2,480.99m. Net profit reached ₹180.52m compared to ₹178.00m in Q2 FY26 and ₹176.53m in Q1 FY27, with diluted EPS at ₹8.56. In leadership changes, MD Hitesh Windlass was appointed Chairman effective 5th Nov'26, while founder Ashok Kumar Windlass stepped down as Whole-time Director to transition into the Senior Management Personnel role of Founder President from 6th Nov'26.
Original exchange filing (PDF)
More announcements from Windlas Biotech Ltd
- Q2 & H1 FY27 Earnings Conference Call Transcript · 13 Nov 2026
- Recording of Conference Call · 07 Nov 2026
- press release titled 'Windlas Biotech Limited Reports its H1 & Q2 FY27 Financial Results" · 05 Nov 2026
- resignation of Mr. Ashok Kumar Windlass (DIN: 00011451) from the position of Whole-time Director and Director of the Company with effect from November 5, 2026 at 10.00 A.M. · 05 Nov 2026
- Investor Presentation - Q2 & H1FY27, · 05 Nov 2026
- Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Approval inter alia unaudited financial results for the quarter and half year ended September 30, 2026 · 05 Nov 2026
- The Board approved inter alia financial results for the quarter and half year ended September 30 2026. · 05 Nov 2026
